Autoimmune Disease Diagnostics Market Worth $7.53 Billion by 2029

Autoimmune Disease Diagnostics Market by Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized), End User (Hospital, Diagnostic Lab, Research)—Global Forecast to 2029

Meticulous Research^®—a leading global market research company, published a research report titled, Autoimmune Disease Diagnostics Market by Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized), End User (Hospital, Diagnostic Lab, Research)—Global Forecast to 2029.’

According to this latest publication from Meticulous Research^®, the autoimmune disease diagnostics market is expected to reach $7.53 billion by 2029, at a CAGR of 6.5% from 2022. The growth of this market is attributed to factors such as the increasing prevalence of autoimmune diseases and the rising technological advancements in autoimmune disease diagnostics. In addition, increasing investments and funding for research related to autoimmune diseases and untapped opportunities in developing countries are expected to provide significant opportunities for the growth of this market.

However, difficulty in diagnosing an autoimmune disease restrains the growth of this market. In addition, an unfavorable reimbursement scenario is a major challenge for the growth of this market.

Autoimmune Disease Diagnostics Market: Future Outlook

The autoimmune disease diagnostics market is segmented based on product, test type, disease type, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on product, in 2022, the reagents, kits, and assays segment is expected to account for the largest share of autoimmune disease diagnostics market. The large market share of this segment is attributed to factors such as the recurrent use of reagents & reagents, the availability of antibodies and other reagents for several test applications, and the increasing number of launches & approvals.

Based on test type, in 2022, the antinuclear antibodies (ANA) segment is expected to account for the largest share of autoimmune disease diagnostics market. The large share of this segment is attributed to factors such as the high prevalence of autoimmune diseases and the high accuracy and simplicity of the ANA test for autoimmune disease testing.

Based on disease, in 2022, the systemic autoimmune disease segment is expected to account for the largest share of autoimmune disease diagnostics market. The large market share of this segment is attributed to the high prevalence of systemic autoimmune diseases such as multiple sclerosis, Type-1 diabetes, and systemic lupus erythematosus.

Based on end user, in 2022, the hospitals segment is expected to account for the largest share of autoimmune disease diagnostics market. The large market share of this segment is attributed to the high volume of tests performed in hospitals & clinics and the high demand for early autoimmune disease diagnosis and treatment.

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), Latin America (Brazil, Mexico, and rest of Latin America), and the Middle East & Africa.

In 2022, North America is expected to account for the largest share of the autoimmune disease diagnostics market, followed by Europe and Asia-Pacific. North America’s major market share is attributed to factors such as high healthcare expenditure, high prevalence of autoimmune diseases, increased awareness among patients regarding autoimmune diseases, and increased funding and investments towards R&D of autoimmune diseases.

Key Players
The key players operating in the autoimmune disease diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Myriad Genetics, Inc. (U.S.), EUROIMMUN Medizinische Labordiagnostika AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).

Download Sample Copy Here:https://www.meticulousresearch.com/download-sample-report/cp_id=5405

Key questions answered in the report:

Which are the high-growth market segments in terms of product, test type, disease type, end user, and region/country?
What was the historical market size for autoimmune disease diagnostics across the globe?
What are the market forecasts and estimates for the period 2022–2029?
What are the major drivers, restraints, opportunities, and challenges in the global autoimmune disease diagnostics market?
Who are the major players in the autoimmune disease diagnostics market?
How is the competitive landscape, and who are the market leaders in the global autoimmune disease diagnostics market?
What are the recent developments in the global autoimmune disease diagnostics market?
What are the different strategies adopted by the major players in the global autoimmune disease diagnostics market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research